title: Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
abstract: Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
authors.affiliation: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, 221002, PR China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhang
authors.forename: Huizhong
authors.initials: H
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Liantao
authors.initials: L
authors.lastname: Li
authors.forename: Baofu
authors.initials: B
authors.lastname: Zhang
authors.forename: Jia
authors.initials: J
authors.lastname: Li
authors.forename: Junnian
authors.initials: J
authors.lastname: Zheng
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins